Emily Paprocki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Emily Paprocki has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Kelsee Halpin
Children’s Mercy Kansas City, Kansas City, MO, USA
4 shared publications - David G. Ingram
Division of Pulmonary and Sleep Medicine, Children's Mercy Kansas City University of Missouri‐Kansas City Kansas City Missouri USA
2 shared publications Benjamin Donald Hoag
CHILDREN’S MERCY HOSPITAL, Lee Summit, MO, USA
1 shared publication- Brian R. Lee
Department of Orthopedic Surgery, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri
1 shared publication David Viskochil
University of Utah Health Salt Lake City Utah USA
1 shared publication- Erica Wee
Division of Endocrinology, Children’s Mercy Kansas City, Kansas City, MO
1 shared publication
Latest Publications
- 4 October 2026
- Published by Wiley in Clinical Endocrinology
International Survey of Growth Hormone and Sleep Evaluation Practices in Infants With Prader‐Willi Syndrome
Objective: Guidelines encourage polysomnogram (PSG) prior to starting growth hormone (GH) in individuals with Prader‐Willi Syndrome (PWS) to avoid adverse effects; however, this presents a challenge in infancy due to barriers regarding access and lack of normative data to guide recommendations. This international survey study assessed clinician practices regarding GH initiation and sleep evaluation in infants with PWS. The primary objective was to determine the prevalence of clinicians reporting they do not always perform a baseline PSG prior to GH Initiation and whether responses were associated with volume of PWS patients seen annually. Design: A survey was distributed through 10 medical societies involved in PWS care. Respondents were grouped by volume of patients with PWS seen annually (/= 21 (high volume, HV) and practice region (United States (US) vs. outside of the US). The primary outcome was evaluated using bivariate analysis, a test for trend, and multivariable logistic regression. All other outcome analyses were considered exploratory. Results: We analysed 141 surveys from 18 countries (primarily US respondents; 79%). There were 58 (41%) LV, 42 (30%) MV, and 41 (29%) HV respondents. With respect to our primary outcome, HV respondents were more likely to answer “not always” when asked whether they perform baseline PSG prior to GH initiation with a decreasing trend to the LV group (HV: 56%, MV: 31%, LV: 26%, p = 0.003). Concurrently, the most common reason to forgo the baseline PSG in the US is to avoid delaying GH start (56%) and less concerns about side effects (apnea, sudden death) in this age group (54%). Outside of the US, the top reason was lack of availability of sleep lab (78%). In multivariable logistic regression, the odds of “not always” obtaining a baseline PSG prior to starting GH in infants was 3.66 times (95% CI: 1.48, 9.04) higher in individuals seeing more than 21 PWS patients (HV) compared to less than 5 (LV) when controlling for respondent's geographic location and years treating patients with PWS ( p = 0.004). Conclusion: High volume PWS clinicians were more likely to report not always obtaining baseline PSG prior to starting GH in infants, primarily to prevent delayed therapy. These findings highlight a gap between guidelines and practice and support the need for prospective outcome data.
- 4 October 2026
- Published by Wiley in Clinical Endocrinology
International Survey of Growth Hormone and Sleep Evaluation Practices in Infants With Prader‐Willi Syndrome
Objective: Guidelines encourage polysomnogram (PSG) prior to starting growth hormone (GH) in individuals with Prader‐Willi Syndrome (PWS) to avoid adverse effects; however, this presents a challenge in infancy due to barriers regarding access and lack of normative data to guide recommendations. This international survey study assessed clinician practices regarding GH initiation and sleep evaluation in infants with PWS. The primary objective was to determine the prevalence of clinicians reporting they do not always perform a baseline PSG prior to GH Initiation and whether responses were associated with volume of PWS patients seen annually. Design: A survey was distributed through 10 medical societies involved in PWS care. Respondents were grouped by volume of patients with PWS seen annually (/= 21 (high volume, HV) and practice region (United States (US) vs. outside of the US). The primary outcome was evaluated using bivariate analysis, a test for trend, and multivariable logistic regression. All other outcome analyses were considered exploratory. Results: We analysed 141 surveys from 18 countries (primarily US respondents; 79%). There were 58 (41%) LV, 42 (30%) MV, and 41 (29%) HV respondents. With respect to our primary outcome, HV respondents were more likely to answer “not always” when asked whether they perform baseline PSG prior to GH initiation with a decreasing trend to the LV group (HV: 56%, MV: 31%, LV: 26%, p = 0.003). Concurrently, the most common reason to forgo the baseline PSG in the US is to avoid delaying GH start (56%) and less concerns about side effects (apnea, sudden death) in this age group (54%). Outside of the US, the top reason was lack of availability of sleep lab (78%). In multivariable logistic regression, the odds of “not always” obtaining a baseline PSG prior to starting GH in infants was 3.66 times (95% CI: 1.48, 9.04) higher in individuals seeing more than 21 PWS patients (HV) compared to less than 5 (LV) when controlling for respondent's geographic location and years treating patients with PWS ( p = 0.004). Conclusion: High volume PWS clinicians were more likely to report not always obtaining baseline PSG prior to starting GH in infants, primarily to prevent delayed therapy. These findings highlight a gap between guidelines and practice and support the need for prospective outcome data.
- Open Access
- 26 June 2023
- Published by Hindawi Limited in Case Reports in Endocrinology
- Vol. 2023, 1-5
Hyperinsulinemic Hypoglycemia and Growth Hormone Deficiency Secondary to 20p11 Deletion
Hypoglycemia is concerning for neurological complications in infants and children. Determining the cause of hypoglycemia is essential in providing appropriate treatment. Hyperinsulinism and growth hormone deficiency are known causes of hypoglycemia but are not commonly found together. We report a 4-month-old boy who presented with severe hypoglycemia and was found to have both hyperinsulinism and growth hormone deficiency. Treatment with both recombinant human growth hormone and diazoxide led to blood glucose normalization. Subsequently, he was found to have a genetic diagnosis of 20p11.22p11.21 deletion. 20p11 deletions have been associated with hypopituitarism, most commonly seen in growth hormone deficiency causing hypoglycemia. This case is one of a few to report hyperinsulinism as a manifestation of this deletion.
- 26 June 2023
- Published by Hindawi Limited in Case Reports in Endocrinology
- Vol. 2023, 1-5
Open AccessHyperinsulinemic Hypoglycemia and Growth Hormone Deficiency Secondary to 20p11 Deletion
Hypoglycemia is concerning for neurological complications in infants and children. Determining the cause of hypoglycemia is essential in providing appropriate treatment. Hyperinsulinism and growth hormone deficiency are known causes of hypoglycemia but are not commonly found together. We report a 4-month-old boy who presented with severe hypoglycemia and was found to have both hyperinsulinism and growth hormone deficiency. Treatment with both recombinant human growth hormone and diazoxide led to blood glucose normalization. Subsequently, he was found to have a genetic diagnosis of 20p11.22p11.21 deletion. 20p11 deletions have been associated with hypopituitarism, most commonly seen in growth hormone deficiency causing hypoglycemia. This case is one of a few to report hyperinsulinism as a manifestation of this deletion.
- 24 November 2022
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 36 (4) , 430-434
Urea as safe treatment for hyponatremia due to syndrome of inappropriate antidiuretic hormone in infant with solitary central incisor and neurofibromatosis-1
Objectives Classic treatment for syndrome of inappropriate antidiuretic hormone (SIADH) is fluid restriction. However, this is not ideal for infants who need large fluid volumes to ensure adequate caloric intake for growth. The use of urea has not been thoroughly studied in children. Case presentation This infant had SIADH complicated by poor growth, solitary central incisor, and NF1. Following failed attempts to correct hyponatremia with fluid restriction and other therapeutics, urea normalized sodium levels and allowed liberalization of formula volumes, which resulted in improved weight gain. Conclusions Urea is a safe, cost-effective, long-term treatment for SIADH in infants who are unable to fluid restrict due to caloric goals.
- 24 November 2022
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 36 (4) , 430-434
Urea as safe treatment for hyponatremia due to syndrome of inappropriate antidiuretic hormone in infant with solitary central incisor and neurofibromatosis-1
Objectives Classic treatment for syndrome of inappropriate antidiuretic hormone (SIADH) is fluid restriction. However, this is not ideal for infants who need large fluid volumes to ensure adequate caloric intake for growth. The use of urea has not been thoroughly studied in children. Case presentation This infant had SIADH complicated by poor growth, solitary central incisor, and NF1. Following failed attempts to correct hyponatremia with fluid restriction and other therapeutics, urea normalized sodium levels and allowed liberalization of formula volumes, which resulted in improved weight gain. Conclusions Urea is a safe, cost-effective, long-term treatment for SIADH in infants who are unable to fluid restrict due to caloric goals.
- Open Access
- 10 November 2022
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 14, 2065-2074
Sleep Disorders in Children with Prader Willi Syndrome: Current Perspectives
Children with Prader-Willi syndrome (PWS) face a multitude of potential health challenges including life-threatening obesity, endocrinopathies, behavioral and emotional dysregulation, developmental delays, and sleep disorders. In the current perspective piece, we provide a focused review of the condition’s etiology and clinical findings, as well as a more in-depth discussion of sleep disorders frequently associated with PWS. In particular, we highlight and discuss difficult clinical scenarios frequently encountered by the pediatric sleep physician caring for this patient population, including diagnosis and treatment of complex sleep-related breathing disorders, considerations for sleep apnea surgery, the interplay between growth hormone and sleep apnea, diagnostic challenges in hypersomnia/narcolepsy, and current and emerging therapies for hypersomnia/narcolepsy. Overall, although there are many areas that need further research, sleep disorders remain a fruitful target for improving quality of life of children with PWS and their families.
- 10 November 2022
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 14, 2065-2074
Open AccessSleep Disorders in Children with Prader Willi Syndrome: Current Perspectives
Children with Prader-Willi syndrome (PWS) face a multitude of potential health challenges including life-threatening obesity, endocrinopathies, behavioral and emotional dysregulation, developmental delays, and sleep disorders. In the current perspective piece, we provide a focused review of the condition’s etiology and clinical findings, as well as a more in-depth discussion of sleep disorders frequently associated with PWS. In particular, we highlight and discuss difficult clinical scenarios frequently encountered by the pediatric sleep physician caring for this patient population, including diagnosis and treatment of complex sleep-related breathing disorders, considerations for sleep apnea surgery, the interplay between growth hormone and sleep apnea, diagnostic challenges in hypersomnia/narcolepsy, and current and emerging therapies for hypersomnia/narcolepsy. Overall, although there are many areas that need further research, sleep disorders remain a fruitful target for improving quality of life of children with PWS and their families.
- Open Access
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A334-A335
A Case Series of Hyperglycemic Hyperosmolar State During the Global COVID-19 Pandemic
Hyperglycemic hyperosmolar state (HHS) is rare in pediatrics, particularly in patients with antibody positive diabetes mellitus (DM). Recent literature has implicated COVID-19 in the reported increase in new-onset DM cases, as well as mixed diabetic ketoacidosis (DKA) and HHS cases, however a rise in HHS cases alone has not been well reported [1,2]. We noted an anecdotal increase in the frequency of HHS cases in our pediatric tertiary care center following the onset of the global COVID-19 pandemic. To investigate further, a retrospective chart review evaluating all patients with DM admitted in the first 6 months of 2019 and the first 6 months of 2020 was conducted. A diagnosis of HHS was defined as a blood glucose over 600 mg/dL with a serum osmolality (calculated or measured) greater than 320 mOsm/kg on initial laboratory evaluation. Patients with DKA, defined as a serum bicarbonate level less than 16 mmol/L with evidence of significant ketosis (serum ketones greater than 3 mmol/L), were excluded from the study. During the first 6 months of 2019, 1 patient met inclusion criteria. However, the diagnosis of HHS was complicated by a concurrent diagnosis of diabetes insipidus, which may have contributed to the hyperosmolar state, and a nonketotic lactic acidosis. Five HHS cases were noted in the first 6 months of 2020, 4 of which occurred in May and June. For the 2020 HHS cohort, the average patient age ± SD was 12 ± 3.34 years. The mean ± SD laboratory values included bicarbonate 18.2 ± 1.64 mmol/L, serum blood glucose 776.8 ± 30.75 mg/dL, calculated serum osmolality 328 ± 4.18 mOsm/kg, and HgA1C 12.72 ± 1.16%. All 5 patients in the 2020 cohort had new-onset DM, with 4 of the 5 patients having at least 1 positive DM antibody (GAD antibodies were positive in 3, ICA/IA-2 antibodies in 2, and Zinc Transporter 8 antibodies in 1). No patients displayed COVID-19 symptoms, and only 1 patient was tested for COVID-19 by PCR, which returned negative. However, SARS-CoV2 antibody testing was not available, and it is unknown if these patients had prior COVID-19 illness. In conclusion, we noted an increased incidence of HHS at our hospital, particularly among new-onset, antibody positive DM patients during the initial months of the COVID-19 pandemic. Further study and investigation are needed to determine the cause of this increased local incidence, and if infectious, social, or economic influences related to the COVID-19 pandemic contributed. References: [1] Chan, K.H., et al., Clinical characteristics and outcome in patients with combined diabetic ketoacidosis and hyperosmolar hyperglycemic state associated with COVID-19: A retrospective, hospital-based observational case series. Diabetes Res Clin Pract, 2020. 166: p. 108279. [2] Unsworth, R., et al., New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care, 2020.
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A334-A335
Open AccessA Case Series of Hyperglycemic Hyperosmolar State During the Global COVID-19 Pandemic
Hyperglycemic hyperosmolar state (HHS) is rare in pediatrics, particularly in patients with antibody positive diabetes mellitus (DM). Recent literature has implicated COVID-19 in the reported increase in new-onset DM cases, as well as mixed diabetic ketoacidosis (DKA) and HHS cases, however a rise in HHS cases alone has not been well reported [1,2]. We noted an anecdotal increase in the frequency of HHS cases in our pediatric tertiary care center following the onset of the global COVID-19 pandemic. To investigate further, a retrospective chart review evaluating all patients with DM admitted in the first 6 months of 2019 and the first 6 months of 2020 was conducted. A diagnosis of HHS was defined as a blood glucose over 600 mg/dL with a serum osmolality (calculated or measured) greater than 320 mOsm/kg on initial laboratory evaluation. Patients with DKA, defined as a serum bicarbonate level less than 16 mmol/L with evidence of significant ketosis (serum ketones greater than 3 mmol/L), were excluded from the study. During the first 6 months of 2019, 1 patient met inclusion criteria. However, the diagnosis of HHS was complicated by a concurrent diagnosis of diabetes insipidus, which may have contributed to the hyperosmolar state, and a nonketotic lactic acidosis. Five HHS cases were noted in the first 6 months of 2020, 4 of which occurred in May and June. For the 2020 HHS cohort, the average patient age ± SD was 12 ± 3.34 years. The mean ± SD laboratory values included bicarbonate 18.2 ± 1.64 mmol/L, serum blood glucose 776.8 ± 30.75 mg/dL, calculated serum osmolality 328 ± 4.18 mOsm/kg, and HgA1C 12.72 ± 1.16%. All 5 patients in the 2020 cohort had new-onset DM, with 4 of the 5 patients having at least 1 positive DM antibody (GAD antibodies were positive in 3, ICA/IA-2 antibodies in 2, and Zinc Transporter 8 antibodies in 1). No patients displayed COVID-19 symptoms, and only 1 patient was tested for COVID-19 by PCR, which returned negative. However, SARS-CoV2 antibody testing was not available, and it is unknown if these patients had prior COVID-19 illness. In conclusion, we noted an increased incidence of HHS at our hospital, particularly among new-onset, antibody positive DM patients during the initial months of the COVID-19 pandemic. Further study and investigation are needed to determine the cause of this increased local incidence, and if infectious, social, or economic influences related to the COVID-19 pandemic contributed. References: [1] Chan, K.H., et al., Clinical characteristics and outcome in patients with combined diabetic ketoacidosis and hyperosmolar hyperglycemic state associated with COVID-19: A retrospective, hospital-based observational case series. Diabetes Res Clin Pract, 2020. 166: p. 108279. [2] Unsworth, R., et al., New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care, 2020.
- Open Access
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A663
Trends in HbA1c Change Among Youth Referred to a Pediatric Type 2 Diabetes Prevention Clinic
Background: Pediatric type 2 diabetes (T2D) has increased in prevalence as childhood obesity rates climb. More youth are being referred to pediatric endocrinology due to the concern for developing T2D, yet prediction of which children will progress to overt T2D is challenging. We describe a single center experience with pediatric prediabetes referrals and trends in HbA1c change. Methods: Retrospective review of new patients seen at a Type 2 Diabetes Prevention (T2DP) Clinic July 2015 - December 2019. All children referred to T2DP Clinic have an elevated BMI and findings of insulin resistance/prediabetes/early T2D. They are evaluated by pediatric endocrinology providers and dieticians at each visit. The outcome of interest was categorical HbA1c change between patients’ initial and most recent T2DP Clinic visit. Only HbA1c measurements conducted at the study site were included to address inconsistencies in lab assays. HbA1c at the initial visit was categorized into 3 groups: 1) < 5.7%; 2) 5.7 to Results: Among 297 patients seen for an initial visit, mean BMI z-score was 2.3 and body fat percentage was 44%. High blood pressure occurred in 47%, high ALT in 24%, low HDL in 14%. Prevalence of initial HbA1c < 5.7%, 5.7 to < 6.5%, and 6.5% to < 8.5% was 46%, 42%, and 12%, respectively. One-third (31%) were prescribed metformin at their initial visit. Only 63 patients (21%) had 2 or more visits in the T2DP Clinic with study site HbA1c data available. Of those 63 patients, mean age at initial visit was 12.5 years, BMI z-score 2.0, and body fat 46%. Most patients were female (68%) with public insurance (70%). Race/ethnicity was 35% black, 29% white, 30% Hispanic. Mean time between initial and most recent HbA1c was 11.9 months. Assessment of categorical HbA1c change showed 14% of patients with progression (n=9), 65% stable (n=41), and 21% with regression (n=13). Female sex, ALT elevation, HbA1c, fasting glucose were found to be statistically different between the groups at baseline (p < 0.05). Age, race/ethnicity, BMI, body fat percentage, elevated blood pressure, lipid profile, 120-minute glucose on OGTT, and metformin use were not different between the groups. Conclusions. Only 14% of children who presented for follow up in our T2DP clinic demonstrated progression in HbA1c. Risk factors for those who progress include female sex and ALT elevation. Further development of predictive models to identify this high-risk population who will progress is necessary. Retaining consistent follow up in pediatric prediabetes clinics presents a challenge.
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A663
Open AccessTrends in HbA1c Change Among Youth Referred to a Pediatric Type 2 Diabetes Prevention Clinic
Background: Pediatric type 2 diabetes (T2D) has increased in prevalence as childhood obesity rates climb. More youth are being referred to pediatric endocrinology due to the concern for developing T2D, yet prediction of which children will progress to overt T2D is challenging. We describe a single center experience with pediatric prediabetes referrals and trends in HbA1c change. Methods: Retrospective review of new patients seen at a Type 2 Diabetes Prevention (T2DP) Clinic July 2015 - December 2019. All children referred to T2DP Clinic have an elevated BMI and findings of insulin resistance/prediabetes/early T2D. They are evaluated by pediatric endocrinology providers and dieticians at each visit. The outcome of interest was categorical HbA1c change between patients’ initial and most recent T2DP Clinic visit. Only HbA1c measurements conducted at the study site were included to address inconsistencies in lab assays. HbA1c at the initial visit was categorized into 3 groups: 1) < 5.7%; 2) 5.7 to Results: Among 297 patients seen for an initial visit, mean BMI z-score was 2.3 and body fat percentage was 44%. High blood pressure occurred in 47%, high ALT in 24%, low HDL in 14%. Prevalence of initial HbA1c < 5.7%, 5.7 to < 6.5%, and 6.5% to < 8.5% was 46%, 42%, and 12%, respectively. One-third (31%) were prescribed metformin at their initial visit. Only 63 patients (21%) had 2 or more visits in the T2DP Clinic with study site HbA1c data available. Of those 63 patients, mean age at initial visit was 12.5 years, BMI z-score 2.0, and body fat 46%. Most patients were female (68%) with public insurance (70%). Race/ethnicity was 35% black, 29% white, 30% Hispanic. Mean time between initial and most recent HbA1c was 11.9 months. Assessment of categorical HbA1c change showed 14% of patients with progression (n=9), 65% stable (n=41), and 21% with regression (n=13). Female sex, ALT elevation, HbA1c, fasting glucose were found to be statistically different between the groups at baseline (p < 0.05). Age, race/ethnicity, BMI, body fat percentage, elevated blood pressure, lipid profile, 120-minute glucose on OGTT, and metformin use were not different between the groups. Conclusions. Only 14% of children who presented for follow up in our T2DP clinic demonstrated progression in HbA1c. Risk factors for those who progress include female sex and ALT elevation. Further development of predictive models to identify this high-risk population who will progress is necessary. Retaining consistent follow up in pediatric prediabetes clinics presents a challenge.
- Open Access
- 7 May 2019
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (6) , 1196-1200
GnRH Agonist Improves Hyperandrogenism in an Adolescent Girl With an Insulin Receptor Gene Mutation
Type A insulin resistance (IR) is caused by heterozygous mutations in the insulin receptor gene. It presents with mild acanthosis nigricans, severe IR, and hyperandrogenism in the absence of obesity or lipodystrophy. Treatment aims to improve insulin sensitivity and decrease androgens. An adolescent female was evaluated for secondary amenorrhea and prominent hirsutism. She had a normal BMI and laboratories revealed elevated LH to FSH ratio (LH 11.6 mIU/mL, FSH 4.2 mIU/mL), testosterone 96 ng/dL (<50), free testosterone 2.21 ng/dL (A(pGly1032Asp)). After standard treatment for hirsutism and hyperinsulinism failed, a trial of GnRH agonist therapy improved hyperandrogenism and reduced ovarian size while severe IR persisted. We describe an adolescent with Type A IR who experienced resolution of clinical and biochemical hyperandrogenism during GnRH agonist treatment. Given the patient’s marked reduction in testosterone and hirsutism despite persistent hyperinsulinism, this case challenges the idea that insulin increases steroidogenesis independently of gonadotropin effect. GnRH agonist therapy should be considered in the treatment of hyperandrogenism in severe cases of IR.
- 7 May 2019
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 3 (6) , 1196-1200
Open AccessGnRH Agonist Improves Hyperandrogenism in an Adolescent Girl With an Insulin Receptor Gene Mutation
Type A insulin resistance (IR) is caused by heterozygous mutations in the insulin receptor gene. It presents with mild acanthosis nigricans, severe IR, and hyperandrogenism in the absence of obesity or lipodystrophy. Treatment aims to improve insulin sensitivity and decrease androgens. An adolescent female was evaluated for secondary amenorrhea and prominent hirsutism. She had a normal BMI and laboratories revealed elevated LH to FSH ratio (LH 11.6 mIU/mL, FSH 4.2 mIU/mL), testosterone 96 ng/dL (<50), free testosterone 2.21 ng/dL (A(pGly1032Asp)). After standard treatment for hirsutism and hyperinsulinism failed, a trial of GnRH agonist therapy improved hyperandrogenism and reduced ovarian size while severe IR persisted. We describe an adolescent with Type A IR who experienced resolution of clinical and biochemical hyperandrogenism during GnRH agonist treatment. Given the patient’s marked reduction in testosterone and hirsutism despite persistent hyperinsulinism, this case challenges the idea that insulin increases steroidogenesis independently of gonadotropin effect. GnRH agonist therapy should be considered in the treatment of hyperandrogenism in severe cases of IR.
- 13 October 2018
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 13 (1) , 142-143
Insulin Pump Adherence Behaviors Do Not Correlate With Glycemic Variability Among Youth With Type 1 Diabetes (T1D)
- 13 October 2018
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 13 (1) , 142-143
Insulin Pump Adherence Behaviors Do Not Correlate With Glycemic Variability Among Youth With Type 1 Diabetes (T1D)